TGTXTG Therapeutics, Inc.
Is the price fair?
Neither cheap nor expensive: modest expectations priced in, but rich vs its sector.
Priced for ~50% a year FCF growth. The price demands less than its three-year revenue growth of 222% a year, expectations look modest.
Sector median 22.6× across 130 covered peers. EV/EBIT counts debt as part of the price, so a cash-rich and a borrowed company can be compared on the same footing.
All from derived, as of Jun 30, 2026.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.
What TGTX's price assumes
TG Therapeutics, Inc. trades at 20.1× earnings against 18.8× for the median Biotechnology name, more expensive than its own group.
Trailing P/E · Biotechnology median 18.8 · 1.07× the median: the market pays up for this one
- Price / sales
- 10.3
Price / sales · today's price, trailing year to Jun 30, 2026
- Free cash flow yield
- 0.21%
Free cash flow yield · Biotechnology median 3.6%
- Growth the price implies
- +50%
Growth the price implies · The price pays for +50% free cash flow growth a year for a decade; revenue has grown +222% a year over the last three.
Details›
- Price / booktoday's price, trailing year to Jun 30, 2026
- 13.6
- EV / EBITtoday's price, trailing year to Jun 30, 2026
- 61.6
- EV / salestoday's price, trailing year to Jun 30, 2026
- 10.5
- Healthcare median P/E509 names
- 26.2
- Biotechnology median P/E244 names
- 18.8
- Free cash flow, trailing twelve months
- $17M
- Market capitalisation
- $8.21B
- 3-year revenue growth
- +222%
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.